ImmuPharma (LON:IMM) Trading 28.8% Higher - Time to Buy?

Key Points

• ImmuPharma's stock price surged by 28.8% during trading, reaching a high of GBX 15.23 and closing at GBX 13.98.
• The company has a market capitalization of £69.86 million and reported a negative P/E ratio of -1,570.67
• ImmuPharma focuses on peptide-based therapeutics for autoimmune diseases, with its lead program being Lupuzor™ for lupus treatment.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 28.8% during trading on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares traded hands during mid-day trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The stock has a fifty day moving average price of GBX 3.12 and a two-hundred day moving average price of GBX 2.91. The company has a market cap of £87.51 million, a P/E ratio of -1,967.53 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.